Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ANVS

Annovis Bio Inc

May 13 • 04:00PM ET

6.85

Dollar change +0.92
Percentage change 15.51	%

Healthcare • Biotechnology • USA • NYSE

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.13	Insider Own	26.05%	Shs Outstand	10.52M	Perf Week	27.09%
Market Cap	75.42M	Forward P/E	-	EPS next Y	-2.43	Insider Trans	0.00%	Shs Float	8.14M	Perf Month	-41.10%
Income	-47.53M	PEG	-	EPS next Q	-0.62	Inst Own	11.99%	Short Float	19.75%	Perf Quarter	-35.32%
Sales	0.00M	P/S	-	EPS this Y	55.87%	Inst Trans	-3.09%	Short Ratio	3.17	Perf Half Y	18.31%
Book/sh	-0.30	P/B	-	EPS next Y	11.53%	ROA	-284.97%	Short Interest	1.61M	Perf Year	-53.84%
Cash/sh	0.29	P/C	24.02	EPS next 5Y	-	ROE	-566.49%	52W Range	4.79 - 22.49	Perf YTD	-63.37%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-126.41%	ROI	-	52W High	-69.54%	Beta	1.78
Dividend TTM	-	Quick Ratio	1.60	Sales past 5Y	0.00%	Gross Margin	-	52W Low	43.01%	ATR (14)	1.62
Dividend Ex-Date	-	Current Ratio	1.60	EPS Y/Y TTM	-43.77%	Oper. Margin	0.00%	RSI (14)	44.40	Volatility	18.28% 28.46%
Employees	6	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.80	Target Price	32.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	91.55%	Payout	-	Rel Volume	1.19	Prev Close	5.93
Sales Surprise	-	EPS Surprise	11.82%	Sales Q/Q	-	Earnings	May 13 BMO	Avg Volume	507.37K	Price	6.85
SMA20	-21.67%	SMA50	-30.07%	SMA200	-33.58%	Trades		Volume	589,333	Change	15.51%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-29-23	Initiated	Canaccord Genuity	Buy	$36
Jul-07-21	Reiterated	Maxim Group	Buy	$45 → $150

May-13-24 01:53PM	ANVS Stock Earnings: Annovis Bio Beats EPS for Q1 2024 (InvestorPlace) +15.51%
07:30AM	Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 07:30AM	Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's Disease (GlobeNewswire) +25.10%
May-06-24 07:30AM	Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders (GlobeNewswire)
Apr-30-24 10:17AM	Canaccord Genuity Cuts Price Target on Annovis Bio to $26 From $36, Maintains Buy Rating (MT Newswires) -23.49%
02:54PM	Loading…
Apr-29-24 02:54PM	Top Midday Decliners (MT Newswires) -59.58%
12:12PM	Annovis Bio Shares Tumble After Drug Candidate Buntanetap for Alzheimer's Misses Efficacy Endpoint in Phase 2/3 Study (MT Newswires)
10:51AM	UPDATE 3-Annovis tumbles as Alzheimer's treatment misses in mid-stage study (Reuters)
10:20AM	CORRECTED- Annovis Bio fails to meet main goal of mid-stage Alzheimer's treatment trial (Reuters)
10:10AM	Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer's Disease (GlobeNewswire)
Apr-24-24 09:55AM	Wall Street Analysts Believe Annovis Bio (ANVS) Could Rally 197.98%: Here's is How to Trade (Zacks) +7.24%
Apr-08-24 09:55AM	Wall Street Analysts See a 218.92% Upside in Annovis Bio (ANVS): Can the Stock Really Move This High? (Zacks)
Apr-02-24 12:53PM	ANVS Stock Earnings: Annovis Bio Misses EPS for Q4 2023 (InvestorPlace) -6.52%
07:30AM	Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Apr-01-24 08:00AM	Annovis Announces Publication That Supports Understanding of Buntanetap's Mechanism of Action in Humans (GlobeNewswire)
09:55AM	Loading…
Mar-21-24 09:55AM	Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 211.71%: Read This Before Placing a Bet (Zacks) +6.58%
Mar-20-24 07:30AM	Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease (GlobeNewswire) +24.44%
Mar-18-24 08:52AM	Are Options Traders Betting on a Big Move in Annovis Bio (ANVS) Stock? (Zacks)
Mar-06-24 03:33PM	Sell Signal: 3 Stocks to Unload Before the Bubble Bursts (InvestorPlace)
Feb-27-24 08:00AM	Annovis Bio Announces Participation in Forum Discussion at AD/PD 2024 (GlobeNewswire) +10.37%
Feb-26-24 01:14PM	12 $10 Stocks That Will Triple (Insider Monkey) -10.76%
Feb-14-24 07:30AM	Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer's Disease (GlobeNewswire)
Feb-12-24 04:06PM	3 Growth Stocks to Sell in February Before They Bottom (InvestorPlace)
Jan-30-24 08:00AM	Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company's Portfolio (GlobeNewswire) -5.54%
Jan-24-24 08:00AM	Annovis Bio Refines Timeline for Parkinson's Phase III Study Data Announcement (GlobeNewswire) -21.91%
Dec-21-23 04:13PM	These Stocks under $10 Are Poised To Explode (Insider Monkey) +5.12%
Dec-11-23 01:00PM	Annovis Bio to Participate in the 139th Yale CEO Summit (GlobeNewswire) -8.75%
Dec-05-23 07:30AM	Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson's Disease (GlobeNewswire)
Dec-01-23 11:12AM	Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why (Zacks)
07:30AM	Annovis Bio Appoints Andrew Walsh as Vice President Finance (GlobeNewswire)
07:30AM	Loading…
Nov-27-23 07:30AM	Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer's Disease Trial, Exceeding Original Projections (GlobeNewswire) +13.69%
Nov-08-23 05:00PM	Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-23 07:30AM	Annovis Bio Measures Novel Biomarkers in Plasma of Parkinsons Patients (Business Wire)
Oct-31-23 08:00AM	Annovis Bio Announces Pricing of $7.5 Million Public Offering (Business Wire) -18.90%
Oct-30-23 04:48PM	Annovis Bio Announces Launch of Proposed Public Offering (Business Wire)
04:42PM	Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimers Disease Patients From the Independent Data and Safety Monitoring Board (DSMB) (Business Wire)
Oct-24-23 09:13AM	Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference (Business Wire)
Oct-18-23 08:30AM	Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More (Zacks) -7.31%
Oct-16-23 10:47AM	CHMP Endorses Merck's (MRK) Keytruda Expansion in Gastric Cancer (Zacks)
Oct-13-23 12:42PM	Annovis (ANVS) AD Study to Continue as Planned, Shares Rise (Zacks) -6.54%
Oct-12-23 11:29AM	Incyte (INCY) Posts Upbeat Data From Phase II Vitiligo Study (Zacks) +9.22%
11:10AM	PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data (Zacks)
08:02AM	Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer's Study (GlobeNewswire)
Oct-11-23 09:24AM	Novo Nordisk (NVO) Up on Positive Kidney Outcomes Study Update (Zacks)
Oct-10-23 10:24AM	Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro (Zacks)
Oct-09-23 09:49AM	Coherus (CHRS) Stock Rises on BLA Re-Filing for Udenyca Onbody (Zacks) -7.26%
08:52AM	Arcutis (ARQT) Up on FDA Nod for Zoryve Label Expansion (Zacks)
Oct-06-23 12:03PM	Merck's (MRK) Meets Goal in Muscle-Invasive Bladder Cancer Study (Zacks)
07:30AM	Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin (Zacks)
Oct-04-23 11:39AM	ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data (Zacks)
09:32AM	Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce (Zacks)
09:27AM	Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies (Zacks)
Oct-03-23 10:45AM	Sanofi (SNY) Inks Deal With J&J to Develop E. coli Vaccine (Zacks)
09:43AM	Apellis' (APLS) Empaveli Injector Gets FDA Nod for PNH (Zacks)
09:11AM	NRx Pharma (NRXP) to Initiate Clinical Study on NRX-101, Stock Up (Zacks)
Sep-29-23 12:32PM	Karuna (KRTX) Submits NDA Filing to FDA for Schizophrenia Drug (Zacks)
Sep-25-23 12:06PM	Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies (Zacks)
12:04PM	FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease (Zacks)
Sep-22-23 12:00PM	Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study (Zacks) -5.36%
11:57AM	Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze (Zacks)
07:57AM	Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC (Zacks)
Sep-21-23 01:23PM	Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab (Zacks)
09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Sep-20-23 10:45AM	FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma (Zacks)
Sep-19-23 08:30AM	Elutias (ELUT) Up on Sale of Orthobiologics Business for $35M (Zacks)
Sep-18-23 01:15PM	PTC Therapeutics (PTCT) Down on Negative CHMP Opinion for DMD Drug (Zacks)
11:39AM	CHMP Endorses AstraZeneca's (AZN) Enhertu in Lung Cancer (Zacks)
Sep-13-23 11:03AM	Avalo (AVTX) Up 45% on Deal to Divest Certain Pipeline Drugs (Zacks) -5.38%
Sep-12-23 11:56AM	Moderna (MRNA), Immatics Ink Deal to Develop New Cancer Therapies (Zacks)
11:49AM	AstraZeneca (AZN) Posts Upbeat Data on Lung Cancer Drug Combo (Zacks)
Sep-11-23 02:43PM	Here's Why You Should Add ANI Pharmaceuticals (ANIP) to Your Portfolio (Zacks)
Sep-07-23 12:58PM	Lisata (LSTA) Up on Positive Updates for Pancreatic Cancer Study (Zacks)
11:28AM	NeuBase (NBSE) Surges 107% on New Shareholder Acquiring Stake (Zacks)
07:57AM	Palisade (PALI) In-Licenses Rights for IBD Candidate, Stock Up (Zacks)
Sep-06-23 10:31AM	BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study (Zacks)
07:46AM	Insmed (INSM) Up on Positive Data From MAC Lung Disease Study (Zacks)
Sep-04-23 12:14PM	FTC Allows Amgen (AMGN) to Proceed With $28B Horizon Buyout (Zacks)
Sep-01-23 02:38PM	InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why (Zacks)
01:27PM	Sage Therapeutics (SAGE) Plunges 46% in a Month: Here's Why (Zacks)
Aug-30-23 11:51AM	Merck's (MRK) Keytruda Receives EU Nod in Gastric Cancer (Zacks)
Aug-29-23 11:32AM	PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why (Zacks)
Aug-28-23 11:42AM	Esperion (ESPR) Aims to Expand Key Drug Labels for Growth (Zacks)
11:38AM	J&J (JNJ) Seeks Full FDA Nod for Rybrevant in Lung Cancer (Zacks)
Aug-24-23 11:50AM	Bionomics (BNOX) Up on Positive Updates on PTSD & SAD Candidate (Zacks)
Aug-22-23 10:26AM	J&J (JNJ) to Keep 9.5% Stake in Kenvue Post Share Exchange (Zacks)
09:39AM	Timber (TMBR) to Get Acquired by LEO Pharma for $36M, Stock Up (Zacks)
Aug-15-23 07:20AM	Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update (Business Wire)
Jul-28-23 12:56PM	3 Biotech Stocks to Buy Before Drug Trials End (InvestorPlace)
Jul-18-23 08:18AM	Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference (Business Wire)
Jun-27-23 07:30AM	Annovis Bio Announces the Filing of a Groundbreaking Patent (Business Wire)
Jun-20-23 12:05PM	Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinsons Disease Patients from the Independent Data and Safety Monitoring Board (DSMB) (Business Wire) +5.22%
Jun-08-23 07:30AM	Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record Pace (PR Newswire)
May-11-23 07:00AM	Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-04-23 09:55AM	Wall Street Analysts See a 213.78% Upside in Annovis Bio, Inc. (ANVS): Can the Stock Really Move This High? (Zacks)
Apr-27-23 07:00AM	Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans (GlobeNewswire)
Apr-25-23 11:36AM	Biogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs (Zacks)
Apr-21-23 10:00AM	Best Momentum Stocks to Buy for April 21st (Zacks) +7.55%
07:10AM	New Strong Buy Stocks for April 21st (Zacks)
Apr-20-23 07:00AM	ANNOVIS BIO PROVIDES UPDATED WEBCAST LINK AND DIAL-IN INFORMATION FOR TODAY'S R&D WEBCAST (PR Newswire)
Apr-19-23 07:30AM	ANNOVIS BIO ANNOUNCES UPDATE ON RECRUITMENT INTO ITS PHASE 2/3 ALZHEIMER'S STUDY AND UPCOMING R&D WEBCAST (PR Newswire) -9.26%

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANVS

Annovis Bio Inc

Upgrade your FINVIZ experience